Abstract
The aim of this paper is to describe the longβterm effect of Uβ500 insulin use on biomedical outcomes in a cohort of patients with diabetes mellitus.
We carried out a case record review of 81 patients from a multicultural population who had received Uβ500 insulin. We recorded data before the introduction of Uβ500 and at data collection (February 2007) including: demographic information, weight, insulin dose, HbA~1c~, lipid profile and blood pressure.
The results showed that the mean duration of treatment was 30Β±22.6 months (range 1β98). The median insulin dose was 292 vs 320 units/day (range 122β600 vs 120β760 units/day). Mean HbA~1c~ at baseline improved from 10.0Β±1.8% to 8.7Β±2.0% (p<0.0001). Patients using Uβ500 insulin for a longer period (>36 months) showed a greater reduction in HbA~1c~ (1.8Β±1.5% vs 0.99Β±1.8%, p<0.05). An improvement in HbA~1c~ was seen in all ethnic groups. Mean total cholesterol reduced from 4.9Β±1.4mmol/L to 4.3Β±1.0mmol/L (p<0.0001) and triglycerides from 4.3Β±4.5mmol/L to 3.0Β±3.0mmol/L (p<0.001). Significant weight gain was seen.
It was concluded that longβterm glycaemic control improved with the use of Uβ500 Human Actrapid in all ethnic groups (p<0.05) at the expense of weight gain.
Uβ500 Human Actrapid is a valuable treatment option in patients with diabetes and severe insulin resistance. Copyright Β© 2010 John Wiley & Sons.